Binary Outcomes Are Not Better than Continuous Variables in Randomized Controlled Trials  by Kottner, Jan & Streiner, David L.
seen in the context of what we exclusively
focused on, i.e., clinical outcomes for
inflammatory skin diseases.
Third, we believe that results expressed
at the group level are much more mean-
ingful for the clinician if the outcome
variable has been dichotomized. We
often fail to interpret dispersion around
the mean and this inability may mislead
our judgment. Following is an example of
two presentations of the same data set.
Without dichotomization: ‘‘In group A,
PASI score had improved of 49% on
average (standard deviation: 33%)
whereas in group B, PASI score had
improved of 42% (90%)’’. With a PASI75
dichotomization: ‘‘PASI75 was achieved
by 32 (33%) in group A and 64 (67%) in
group B’’. We have of course no objec-
tion for reporting the results for both a
quantitative and qualitative parameter.
Internal validity of the trial is unaffected
by the supplementary presentation and
analysis of dichotomized outcomes.
Fourth, we agree with Kottner and
Streiner (2013) that randomized trials
should be distinguished from clinical deci-
sion-making. However, in medical prac-
tice, outcome assessment is closely related
to decision, and a decision is always, at
the end, a binary choice: ‘‘to treat or not
to treat’’, ‘‘to carry on or to stop’’, ‘‘to
increase the dose or not’’, and so on.
For all the above-mentioned reasons,
we see dichotomization of continuous
outcomes not only perfectly justifiable
in most cases but also desirable in order
to increase external validity without
altering the internal validity of clinical
trials.
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TO THE EDITOR
We read the systematic review by Nassar
et al. (2013) in the February 2013 edition
of the Journal of Investigative Derma-
tology with great interest. The need for
clear definitions, operationalizations, and
bias-free measurements of primary
outcomes in randomized controlled trials
(RCTs) in dermatology and other fields to
enhance internal and external validity of
results cannot be overemphasized. The
authors provide valuable insights that can
be used to improve RCT design and
outcome planning. However, the plea
for dichotomizing outcomes seems to be
a bit surprising. The statement ‘‘y
regardless of the disease, we believe that
attributing to the patient a binary value
conveys a general benefity’’ (Nassar
et al., 2013, p 374) and the relating
assumptions are problematic and need
to be explored further.
The obvious and widely acknowledged
limitation for dichotomizing continuous
variables is the loss of statistical power
and the loss of precision of outcome
estimates (Streiner, 2002). These are not
only ‘‘statistical drawbacks’’ (Nassar et al.,
2013, p 374), but may cause very practical
problems in clinical research practice.
Reducing the risk of type II error by
ensuring adequate power is one of the
most important quality criteria of RCTs.
When power is sacrificed owing to
dichotomizing continuous variables, this
can only be compensated by increasing
the sample size. Increasing the sample size
increases costs and study durations, which
are always a challenge in clinical research.
Sample sizes that are unnecessarily increa-
sed might also be judged unethical. The
number of participants should be mini-
mum to achieve the study objective, but
including too many subjects may cause
additional burden and may put a number
of patients at extra risks (Julious, 2004).
The assumption that ‘‘y a binary
expression is directly related to the
therapeutic decisiony’’ (Nassar et al.,
2013, p 374) might be true only in cases
where the variable by its very nature is
already a dichotomy like the presented
example of ‘‘dead’’ versus ‘‘alive’’. In all
other cases, dichotomization of a conti-
nuum is an unjustified oversimplification
of a complex reality. Dichotomizing, for
instance, cholesterol, body mass index,
transepidermal water loss, or the Derma-
tology Life Quality Index (DQLI) (Finlay
and Khan, 1994), implies that the chosen
cutoff points adequately categorize
individuals into two groups. Even if there
is consensus about this cutoff today, this
cannot be taken for granted in future.
There are various examples in medicine
and allied health sciences that, in the light
of newer evidence and insights, cutoff
values and ranges need to be adapted to
(National Heart, Lung, and Blood Institute,
2002; World Health Organization, 2006).
Far more important is the fact that catego-
rization causes artificial discontinuities.
For instance, DLQI scores ranging from
11 to 20 are interpreted as having a ‘‘very
large effect on the patient’s life,’’ and
scores ranging from 21 to 30 areAccepted article preview online 11 June 2013; published online 11 July 2013
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interpreted as having an ‘‘extremely large
effect on patient’s life’’ (Hongbo et al.,
2005). Imagine you want to evaluate the
effect of a treatment on the patient’s
quality of life that is extremely affected
by a dermatological disease (DLQI scores
between 21 and 30). You define success
when the score after the treatment is
between 11 and 20, because it is
considered clinically relevant. After
treatment, scores of one patient decrease
from 29 to 22, and scores of another
patient decrease from 22 to 18. Thus,
the treatment improved the quality of life
by seven points in case one, and by four
in case two. However, according to the
chosen cutoff score, only the latter would
be called ‘‘success,’’ although the
treatment effect was much lower.
Dichotomization blurs the sizes of
treatment effects, and it is therefore not
‘‘more clinically meaningful’’ (Nassar
et al., 2013, p 374).
Finally, we recommend not confusing
outcome measurements in RCTs with
clinical decision-making (Streiner, 2002).
RCTs are conducted to demonstrate
superiority, equivalence, or noninferiority
of treatment effects. As such, they must be
designed to maximize their internal
validity (Shadish et al., 2002)—that is, to
reduce bias and to increase the
probability of finding a difference when
one exists (i.e., power). This is best
achieved when the outcome variable
more closely matches the phenomenon
being studied. When that phenomenon is
itself a continuum, then its measurement
should be on a continuum. After—and
only after—the study has determined
whether there is a relationship between
the independent and dependent variables,
clinicians can then use this information to
make decisions regarding treatment.
Techniques, such as receiver operating
characteristic analysis, can be used to
determine optimal cutoff points (Streiner
and Cairney, 2007). As we mentioned
previously, these cutoff points can later be
changed in the light of new information,
but this can be done only if the outcome
had been measured on a continuum to
begin with, and cannot be done if the
outcome had been dichotomized a priori.
We completely agree with Nassar et al.
(2013) on the importance of primary
outcome constructions in dermatology
and other fields. The decision on
outcome variables should be based on
the objective of the RCT, on the validity
and reliability of the operationalization,
on the clinical relevance, and on avail-
able resources. Because parametric vari-
ables allow stronger inferences with
smaller sample sizes, they have advant-
ages over binary variables. If the outcome
in an RCT is measured on a continuum, it
should never be dichotomized.
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TO THE EDITOR
The mobilization and migration of epi-
dermal Langerhans cells (LCs) to
draining lymph nodes is dependent
upon receipt of (at least) two indepen-
dent cytokine signals; one provided by
IL-1b and the second by tumor necrosis
factor-a (TNF-a) (Cumberbatch et al.,
1997). Approximately 20–30% of epi-
dermal LCs are mobilized in response to
these signals (Griffiths et al., 2005).
Attention has focused recently on the
potential importance of LCs in un-
involved skin sites of patients withAccepted article preview online 28 June 2013; published online 25 July 2013
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